Abstract. Combining data from several case-control genome-wide association (GWA) studies can yield greater efficiency for detecting associations of disease with single nucleotide polymorphisms (SNPs) than separate analyses of the component studies. We compared several procedures to combine GWA study data both in terms of the power to detect a disease-associated SNP while controlling the genome-wide significance level, and in terms of the detection probability (DP ). The DP is the probability that a particular disease-associated SNP will be among the T most promising SNPs selected on the basis of low p-values. We studied both fixed effects and random effects models in which associations varied across studies. In settings of practical relevance, meta-analytic approaches that focus on a single degree of freedom had higher power and DP than global tests such as summing chisquare test-statistics across studies, Fisher's combination of p-values, and forming a combined list of the best SNPs from within each study.
INTRODUCTION
Case-control genome-wide association (GWA) studies are used to detect associations of disease with genetic markers (alleles of single nucleotide polymorphisms or SNPs) across the genome by compar-ing individuals with disease (cases) to disease-free individuals (controls). A widely accepted approach for identifying and confirming an association is to conduct an initial discovery study to detect promising SNPs and then to validate the associations in data from independent studies, as, for example, in Easton et al. (2007) . Both power calculations (e.g., Skol et al., 2007) and calculations of the probability of detecting disease-associated SNPs (Gail et al., 2008a) indicate that large numbers of cases and controls are needed for a successful discovery study if one is interested in common alleles with small odds ratios (e.g., odds ratio per allele = 1.2), such as have been found in GWA studies for breast (Easton et al., 2007) and prostate (Yeager et al., 2007) cancer. A recent study of diabetes (Zeggini et al., 2008) illustrated that combining data from several studies could improve discovery efforts, compared to the separate analyses of the component studies. In some diseases, such as thyroid cancer or amyotropic lateral sclerosis (ALS), it is not possible to accrue large numbers of cases and controls in a single region or study center; in this context, data will need to be combined for successful discovery. In this paper we compare several approaches to using data from several smaller GWA studies to discover promising disease-associated SNPs that require further validation studies.
We compare procedures to combine data from genome-wide association studies both in terms of the power to detect a disease-associated SNP while controlling the experiment-wide (including genome-wide) significance level, and in terms of the detection probability. The detection probability is the probability that a particular disease-associated SNP will be among the T most promising SNPs selected on the basis of low p-values (or high chi-square tests).
In Section 2 we describe models for disease association, including a fixed effects model that assigns the same log-odds ratio to each disease SNP and a random effects model that allows this log-odds ratio to vary across studies. In Section 3 we review the concept of detection probability for a single GWA study and extend the concept for several procedures for combining data from S case-control studies. We also define and compute power for these procedures, while controlling the experiment-wide significance level (Section 4). Section 5 contains numerical results to compare procedures with respect to detection probability and power. Some conclusions are given in Section 6.
DATA AND MODELS
We assume that genotypes for N SNPs from the same genotyping platform are available for case-control studies s = 1, . . . , S. In this paper we let N = 500,000. Study s includes n s cases and n s controls. Let X i = 0, 1 or 2 be the number of minor alleles at locus i for i = 1, . . . , N , and let Y = 1 for diseased and 0 for nondiseased subjects. Suppose SNPs 1, . . . , M are associated with disease, while SNPs M + 1, . . . , N are not, resulting in the model for disease
Thus, we assume that the log-odds ratios for the nondisease-associated SNPs are equal to zero. In numerical studies in Section 5, we assume that all disease-associated SNPs have the same log-odds ratio within a study, β s i = β s for i = 1, . . . , M and for s = 1, . . . , S. We model variation of β s among studies in two ways. In the fixed effects model we set β s = β for s = 1, . . . , S, as might happen if the cases and controls for the S studies were sampled from the same homogeneous population. Under a random effects model, the log-odds ratios for the disease related SNPs are independent normal variables, β s ∼ N (β, τ 2 ), s = 1, . . . , S. As tagging SNPs are typically only markers in linkage disequilibrium (LD) with the true causal disease SNPs, this model captures the impact of variation in LD patterns on β s across study populations.
We have assumed that log-odds ratios are strictly zero for the N − M nondisease-associated SNPs. This "strong null hypothesis" is plausible because, if there is no nearby disease SNP, then no amount of LD among nearby SNPs can induce an association between a marker SNP and disease.
METHODS TO COMPUTE DETECTION PROBABILITY FROM COMBINED STUDIES

Review of Detection Probability for a Single
Case-Control GWA Study
In a single GWA study, if disease is rare and the SNP scores X i are independent in the source population,
in the case-control population (Gail et al., 2008a) 
, where π 1 is the proportion of cases in the source population that are in the case-control study, and π 0 is the analogous proportion for controls. E is the expectation operator.
The null hypothesis of no association for the ith SNP, H 0 : β i = 0, can be tested using the Wald statistic for a trend in risk with the number of minor alleles, W i =β 2 i / var(β i ), whereβ i denotes the maximum likelihood estimate for model (2) and its variance var(β i ) is computed under the retrospective sampling (Gail et al., 2008a) . Alternatively, one could use the score test for trend (Armitage, 1955) . Under the null hypotheses of no association, both the Wald and the score test have one degree of freedom chisquare (χ 2 1 ) distributions. These tests correspond to additive (or codominant) genotype scores (Sasieni, 1997) and yield the same value whether the major or minor allele is positively associated with disease (Devlin and Roeder, 1999; Pfeiffer and Gail, 2003) . Moreover, under the rare disease assumption, the W i are independent, which facilitates the calculation of detection probability (Gail et al., 2008a) .
A particular SNP, for example, SNP k, is T-selected or simply selected if its associated Wald statistic (or p-value) is among the top T test statistic values (or T lowest p-values), that is, rank(W k ) > N − T . The probability that a particular disease-associated SNP, for example, SNP i, is T -selected is the detection probability (DP ), that is, DP = P (rank(W i ) > N − T ). The proportion positive (PP ) is the fraction of selected SNPs that are true disease-associated SNPs.
Combined List of SNPs
Here, each of the S studies is analyzed separately. The Wald test statistics W s j , j = 1, . . . , N , based on model (2) are ranked within study s, for s = 1, . . . , S, and in each study the top T /S SNPs are selected. We then create a "combined list" of the union of the sets of T /S SNPs selected from each study. We let T c be the number of distinct SNPs that are T /S selected in at least one of the S studies. T c is not a fixed number, but a random variable, with T /S ≤ T c ≤ T , depending on the amount of overlap among the top T /S SNPs from the S studies.
As the S studies are independent, the probability that disease SNP i is T /S selected in k out of S studies is given by
where DP s i denotes the detection probability for the ith disease SNP in study s, that is, DP
, and the sum is over all S!/k!(S − k)! ways of selecting the set of k indices, A k , from the set {1, . . . , S}. DP s i is computed either under a fixed effects or random effects model for the log-odds ratios of the disease-associated SNPs. If the studies are exchangeable and DP s i = DP i for all s, P (SNP i T /S-selected in k studies) simplifies to a binomial probability and the expected number of studies that T /S-select the ith disease SNP is S(DP i ).
The combined detection probability, namely, the probability that the ith disease SNP is T /S selected in at least one of the S studies, is
For special settings, analytic expressions for DP i s given in Gail et al. (2008a) can be used in (3) to approximate DP i . When all the studies have the same sample size and when there is only a single diseaseassociated SNP, M = 1, that has the same fixed logodds ratio β in (2) for each individual study,
In expression (4) χ 2 1,1−T /SN denotes the 1 − T /SN quantile of a central χ 2 1 distribution, and F H 1 denotes a noncentral chi-square distribution χ 2 1 (δ) with non-centrality δ = β 2 /σ 2 1 , where σ 2 1 is given in equation (21) in the Appendix.
The expected proportion of positive findings out of the T c SNPs is approximately
because, as demonstrated in simulations (Section 5.1), there is very little overlap among selected SNPs across studies and, therefore, T c is usually close to T .
Pooled Individual Level Data
We show in Section 3.4 that a meta-analytic approach has equivalent efficiency to pooling individual level data. Therefore, in numerical studies below we only use the meta-analytic approach. Nonetheless, it is instructive to outline an analysis of individual level data from S studies with the following fixed effects model.
We assume that the log-odds parameter, β i , for disease SNP i is the same in all studies, leading to
. . , S, where µ * s denotes the study-specific intercept that accommodates differences in disease prevalence and differences in sampling fractions among the different studies. The Wald statistic for the ith SNP is computed by first finding the estimateβ i that maximizes the likelihood
The information matrix to compute the variance of β i depends on the study specific intercepts µ s . An expression for var(
Si is provided in equation (20) in the Appendix. The corresponding Wald test
Si has a central χ 2 1 distribution if β i = 0 and a noncentral χ 2 1 (δ) distribution with δ = β 2 i /σ 2 Si otherwise. Selection of the top T SNPs is based on ranking the Wald statistics W i , i = 1, . . . , N , computed from model (5). If M = 1, n s = n, and β s i = β i for s = 1, . . . , S, then, following Gail et al. (2008a) ,
where F H 1 is a noncentral χ 2 1 (δ) distribution with noncentrality parameter δ = β 2 i /σ 2 Si .
Meta-Analytic Approaches
We first estimate study-specific log-odds ratiosβ s i for the ith SNP, i = 1, . . . , N , by fitting model (2) separately to each SNP for each study and then combine study specific maximum likelihood estimatesβ s i to obtain an overall estimate of disease association for the ith SNP. This can be done using a fixed effects model (Mantel and Haenszel, 1959; Yusuf et al., 1985) or a random effects model (DerSimonian and Laird, 1986) for disease SNPs.
For the fixed effects model, the combined SNP specific estimate isβ
Under the null hypothesis of no association,β F i has an asymptotic normal distribution with mean zero and variance var(β F i ) = ( S k=1 1/σ 2 ki ) −1 . As shown in the Appendix, var(β F i ) = σ 2 Si , the variance of the maximum-likelihood estimate based on model (5). Thus, the two approaches are equally efficient under the fixed effects model and in Section 5 we only study the meta-analytic approach.
Under a random effects model (DerSimonian and Laird, 1986) , estimatesβ s i are assumed to follow a linear model,β s i = β s i + ǫ s i , where β s i is a normal variate with mean β i and variance τ 2 i , the ǫ s i are normally distributed with mean zero and variance σ 2 is , and β s i and ǫ s i are independent. Thus, under the random effects model var(β s i ) = σ 2 is + τ 2 i . Note that this model is equivalent to the random effects model for disease SNPs in Section 2 and that E(β s i ) 2 = β 2 +σ 2 is +τ 2 i , which can be large even when β = 0. The strong null hypothesis for nondiseaseassociated SNPs, however, corresponds to a fixed effects model with β i = 0 or, equivalently, to a degenerate random effects model with β s i = 0 and τ 2 i = 0.
Replacing the σ 2 is by their estimates reported in the individual studies, we have (DerSimonian and Laird, 1986) 
where u is = 1/σ 2 is andβ F i is given by (8). The random effects meta-analytic estimate of the association of the ith SNP with disease is then given bŷ
In order for the between study variance τ 2 i to be reliably estimated, the number of studies S cannot be too small. For the fixed effects model,β F i becomes asymptotically normal as n S increase. For the random effects model,β R i becomes asymptotically normal as S increases.
The detection probabilities are computed by ranking the Wald statistics
Si , for the fixed effects meta-analytic approach, or
for the random effects meta-analytic approach.
Sums of Test Statistics and Fisher Combination of p-Values
Let W s i denote the Wald test statistics for SNP i in study s obtained from fitting (2) to the studyspecific data. The combined test statistic is
which, for the nondisease-associated SNPs, has a central χ 2 S distribution. For the disease-associated SNPs, and conditional on β s i , W i has a noncentral χ 2 S (δ) distribution with noncentrality parameter δ = S s=1 (β s i ) 2 /σ 2 is . For M = 1 and β s 1 = β, the detection probability is well approximated by (7). For this special case δ = β 2 S/σ 2 1 , where σ 2 1 is specified in the Appendix formula (21).
Instead of combining the Wald statistics, one can combine p-values p s i across studies, through p c i = S s=1 p s i (Fisher, 1932) , and rank SNPs based on p c i . Under the null hypothesis, −2 log
Numerous other combinations of p-values have been proposed and studied (Loughin, 2004) . We therefore also assessed the performance of the Liptak-Stouffer combination of p-values, given by LS =
that has a normal distribution with mean zero and variance one under the null hypothesis (Liptak, 1958) .
POWER OF VARIOUS APPROACHES TO COMBINING GWA STUDIES
Except for the Fisher and Liptak-Stouffer methods of combining p-values, we computed the statistical power of the approaches to combining data presented in Sections 3.2-3.5 analytically based on asymptotic theory, and also tested analytical results in simulations. The power is the probability that the test statistic for a given SNP will fall into the predetermined critical region that is chosen to control the significance level for multiple testing of the N genotypes and S studies. In contrast to the ranking procedures for detection probabilities, the power for any particular SNP does not depend on the test statistic for any other SNP. We therefore usually omit the SNP index in what follows. The rejection region is chosen based on the strong null hypothesis that the log-odds ratios for the nondisease-associated SNPs are always equal to zero, regardless of the model that gives rise to the effects for the disease-associated SNPs.
We set α = 0.05/N = 10 −7 to account for multiple testing. Further control of multiplicity for S is described below.
Combine Lists of Significant SNPs from Each Study
As in Section 3.2, we compute study-specific Wald statistics W s j , j = 1, . . . , N , s = 1, . . . , S, based on model (2). We determine significance based on whether W s j exceeds the significance threshold χ 2 1,1−α , the 1 − α quantile of a χ 2 1 distribution. As we are combining results from S studies, we replace α by α/S to control the experimentwise error at 0.05. An exact calculation replaces α by α * = 1 − (1 − α) 1/S , but for small α this α * is very nearly α/S.
The power of the combined list approach under an alternative H 1 is thus
When all the disease-associated SNPs for the different studies have the same fixed effect, β s = β, P H 1 is generated by a χ 2 1 (δ) distribution with δ = β 2 /σ 2 1s , where σ 2 1s is given in equation (21) in the Appendix. When all the studies have the same sample size, then (11) reduces to 1 − [F H 1 (χ 2 1,1−α/S )] S , which is equivalent to (4) with T = αN .
To obtain the power when the log-odds ratios of the disease-associated SNPs arise from the random effects model, β s ∼ N (β, τ 2 ), s = 1, . . . , S, we integrate (11) over the distribution of the independent study specific β s parameters to obtain
where F denotes the normal distribution with mean β and variance τ 2 .
Meta-Analytic Approaches
Fixed effects meta-analytic approach Based on asymptotic normal theory, the power for the test
Under the fixed effects model for the disease-associated SNPs, P H 1 is generated by a χ 2 1 (δ) distribution with δ = (β F ) 2 /σ 2 S , where
and σ 2 S is given in the Appendix equation (20) . The power under the random effects model for disease-associated SNPs is obtained by integrating equation (12) over the distribution of β s , namely,
Random effects meta-analytic approach The use of asymptotic normal theory for the random effects meta-analytic approach when there are few studies is problematic, as the type I error rate can be substantially inflated (Follmann and Proschan, 1999) . Follmann and Proschan therefore suggest using a t S−1 reference distribution rather than a standard normal distribution. Using the t-approximation, the power of the random effects meta-analytic approach is
where P H 1 is generated by a noncentral F 1,S−1 distribution, with noncentrality parameter δ = (β R ) 2 /σ 2 , and F 1,S−1,α is the 1 − α quantile of a central F 1,S−1 distribution. However, under the strong null hypothesis that the log-odds ratio parameters for the nondisease-associated SNPs are strictly zero and do not vary across studies, one can replace the F 1,S−1,1−α cutoff value in (13) by χ 2 1,1−α , as for the fixed effects meta-analytic approach. In simulations we study the power for the random effects metaanalytic approach using both cutoff values for the test statistic.
The power under the random effects model is obtained by integrating equation (13) or P H 1 (W R > χ 2 1,1−α ), over the random effects distribution of the β s , similar to the fixed effects meta-analytic approach given above.
Power of the Sum of Test Statistics
The power for the test statistic W = S s=1 W s is given by
where P H 1 is generated by a χ 2 S (δ) distribution with δ = S s=1 (β s ) 2 /σ 2 s . We do not compute the power for Fisher's −2 S s=1 log p s or the Liptak-Stouffer combination of p-values analytically, because the distribution of the S p-values p 1 , . . . , p S cannot be obtained in a manageable form under the alternative.
SIMULATIONS
Simulation Methods to Estimate the Detection Probability, DP
We used the methods in Gail et al. (2008a) for a single study to simulate data separately from each of the case-control studies, s = 1, . . . , S. At each SNP i = 1, 2, . . . , N , we randomly and independently selected a minor allele frequency, η i , from the distribution of minor allele frequencies in CGEMS (https://caintegrator.nci.nih.gov/cgems/), as described in Gail et al. (2008a) . In each replicate of the simulations described below, minor allele frequencies were re-assigned to each SNP in this way. We assumed that the N genotypes were statistically independent in the source population, the disease is rare and the Hardy-Weinberg equilibrium holds at each locus. Given β i , we sampledβ i from N (β i , σ 2 i (β i )) independently for each i = 1, . . . , N to generate realizations of the Wald statistics rapidly in GAUSS (Aptec Systems, 2005) . The Wald statistics were computed as W i =β 2 i /σ 2 i (β i ), which has the same asymptotic distribution asβ 2 i /σ 2 i (β i ).
For each disease model and parameter setting we generated NSIM = 1000 independent simulations. Under either the fixed or random effects disease model, and conditional on η i and β s , we computed σ 2 s = var(β s ) and then drewβ s from N (β s , σ 2 s ). The studyspecific estimates were then used in the procedures in Sections 3.2, 3.4 and 3.5 to compute DP .
Define I(m, ISIM , T ) = 1 if the rank of the corresponding test statistic falls into the top T ranks of the N ranked values of the test statistics in simulation ISIM , and 0 otherwise. The detection probability for each approach is then estimated by
PP was estimated from PP = ( DP)M/T . For the combining lists approach, we modified these formulas to take into account variation in T c . Letting I(m, ISIM , T /S) = 1 if the disease SNP is T /S-selected in any study in simulation ISIM and 0 otherwise, we estimated DP as above with I(m, ISIM , T /S) in place of I(m, ISIM , T ), and we estimated
, where T c (ISIM ) is the cardinality of the union of the S T /S-selected sets of SNPs.
Simulations to Estimate Power
We estimated power by simulations for each of the procedures in Section 4. We fixed the allele frequency for the disease-associated SNP at η = 0.2673, the mean allele frequency used in the DP calculations. Estimatesβ were otherwise obtained as in Section 5.1, but for a single locus.
We used NSIM = 100,000 replicates of outcome data and for each replicate, each of the test statistics was calculated, and the true power estimated as the proportion of replicates which were significant at the experimentwise level α = 10 −7 .
Simulation Results for Detection Probability
We evaluated the DP for T = 20, 100, 1000, 10,000 and 25,000, which, when divided by N, corresponds to respective selection fractions 0.00004, 0.0001, 0.0005, 0.02 and 0.05. We studied M = 1 and M = 10 disease SNPs, and let S = 5 with n s = 400 cases and controls and S = 10 with n s = 200 cases and controls for both the fixed and the random effects models for β, and we focused on β = log(1.3). To assess the impact of varying study sizes, with S = 5, we let n 1 = 1000 and n s = 250, s = 2, . . . , 5. Table 1 Detection Probability (DP) and Proportion Positive (PP) in percent for five methods of combining data from S studies with ns cases and ns controls for fixed effects models with β = log(1.3), N = 500,000 SNPs, and random allele frequency η Method T = 20 T = 100 T = 1000 T = 10,000 T = 25,000 DP PP DP PP DP PP DP PP DP PP For the fixed effects model (Table 1) , the two metaanalytic approaches had the highest DP for all study designs, followed by Fisher's combination of p-values and then the sum of the Wald statistics. The "combined list approach" had the lowest DP of all approaches. For example, for T = 20, DP for the list was only 7.2% for five studies with n s = 400 cases and 400 controls each, and a single true diseaseassociated SNP, M = 1, while DP was 53.9% and 58.4% for the sum of Wald tests and the Fisher pvalue combination respectively, and 74.2% for both meta-analytic approaches. In the same setting, for T = 25,000, DP for the combined list approach was 85.3%, while it was 94% or higher for all other approaches (Table 1) . For S = 10 and n s = 200, the combined list approach had even smaller DP values, because each of the component studies had a very small DP . Similar patterns were observed for M = 10. The number of disease-associated SNPs, M , did not strongly impact DP for any of the methods under the fixed effects model. For S = 5 and varying study sizes, n 1 = 1000 and n s = 250, s = 2, . . . , 5, for M = 1, the performance of the combined list approach was slightly better, with DP = 22.0% for Table 2 Detection Probability (DP) and Proportion Positive (PP) for five methods for combining data from S studies, with ns cases and ns controls for the random effects model for β ∼ N (log(1.3), 0.05 2 ), with N = 500,000 SNPs, and random allele frequency η Method T = 20 T = 100 T = 1000 T = 10,000 T = 25,000 DP PP DP PP DP PP DP PP DP PP T = 20, because study s = 1 had a larger size and higher DP . The proportions positive (PP ) were largest for small T and larger M . As T increased, DP increased but PP declined (Table 1) . If the purpose of the study is to serve as an initial screen designed to capture disease SNPs but tolerate a large number of false positive results (i.e., very small PP ), T = 25,000 might be of interest. If the purpose is to select a small number of promising SNPs for further study, data for T = 20 commend the meta-analytic approaches. For the settings we studied, the LiptakStouffer combination of p-values had a lower DP than Fisher's combination of p-values. For example, for S = 10 and n s = 400, with M = 1 true diseaseassociated SNP, the values of DP were 55.5%, 64.8%, 76.2%, 86.9% and 91.2% for the Liptak-Stouffer combination for T = 20, 100, 1000, 10,000 and 25,000, while the corresponding DP values of the Fisher combination were 58.4%, 66.9%, 80.2%, 90.8% and Table 3 Detection Probability (DP) and Proportion Positive (PP) for five methods for combining data from S studies, with ns cases and ns controls for the random effects model for β ∼ N (log(1.3), 0.5 2 ), with N = 500, 000 SNPs, and random allele frequency η Method T = 20 T = 100 T = 1000 T = 10,000 T = 25,000 DP PP DP PP DP PP DP PP DP PP For the random effects model (Table 2 ) with a relatively small between study standard deviation, τ = 0.05, and with β = log(1.3) for the disease-associated SNPs, the DP results were very similar to the fixed effects model. Again, the meta-analytic approaches had better DP than the combined list, sum of Wald tests, or Fisher p-value combinations. However, for the random effects model with a very large standard deviation, τ = 0.5 (Table 3 ), Fisher's combination of p-values and the sum of the Wald statistics had much better DP than the meta-analytic approaches, as the large variation among theβ s for the disease-associated SNPs caused some of them to be negative, reducing the meta-analytic estimate of the overall effect (Table 3 ). For τ = 0.5 the combined list approach also had higher DP than the two meta-analytic approaches. Even for T = 25,000, for S = 5 studies with 400 cases and 400 controls each, and a single true disease-associated SNP, M = 1, DP was 81.5% and 80.0% for the fixed and random effects meta-analytic approaches, compared to 98.3%, 98.7% and 98.8% for the combined list, the sum of Wald statistics and Fisher's combination of p-values (Table 3 ). For T = 20, DP for the combined list approach was considerably lower when the number of disease-associated SNPs was M = 10, because in each study the 10 disease SNPs compete against each other for only T /S = 4 top positions. This competition is less pronounced in Tables 1 and 2 because the magnitude of log-odds ratios for disease-associated SNPs does not reach the large values that sometimes occur in simulations in Table 3 with τ = 0.5. Similar to the fixed effects setting, the Liptak-Stouffer combination of p-values had a lower DP than Fisher's combination of pvalues and the sum of Wald tests for the random effects models with τ = 0.05 and τ = 0.5 and, therefore, we did not tabulate these results.
For fixed effects models (Table 1) , studies with S = 5 and n s = 400 resulted in higher DP than studies with the same total number of subjects but S = 10 and n s = 200 for the combined list, the sum of Wald statistics and Fisher's combination of pvalues, for both M = 1 and M = 10 disease SNPs; no such difference was seen for the meta-analytic approaches. Under the random effects model with τ = 0.05 (Table 2) , DP was higher for the combined list, sum of Wald statistics and Fisher's combination of p-values for S = 5 with n s = 400 than for S = 10 with n s = 200. In this case the meta-analytic procedures had comparable or slightly higher DP for S = 10, n s = 200. Under the random effects model with τ = 0.5 (Table 3) , all procedures except the combined lists had higher DP with S = 10, n s = 200.
Simulation Results for Power
Power estimates based on NSIM = 100,000 simulations are plotted against odds ratios (Figure 1) for S = 5 with n s = 400 and for S = 10 with n s = 200 under the fixed effects model. The odds ratio was assumed to be the same in all S studies. For all combinations of S and n s , the fixed effects metaanalytic approach had the largest power for all oddsratios. It gave the exact same results as the random effects meta-analytic approach with the critical region defined by the χ 2 1,1−α quantile, leading to indistinguishable lines in Figure 1 . Using the F 1,S−1,1−α cutoff value for the random effects meta-analytic approach resulted in extremely low power. Additionally, for the meta-analytic approaches, S = 5 with n s = 400 resulted in the exact same power as S = 10 with n s = 200, as the total sample size was the same. The sum of Wald-test statistics and Fisher's p-value combination gave very similar results with 80% power for odds ratios near 1.4 compared to 93% power for the meta-analytic approaches. The power of the combined list approach was noticeably lower, and reached 80% only for an odds ratio = 1.75. These empirical power estimates agreed well with the analytic power calculations (data not shown).
For the random effects model for the disease-associated SNPs, β s ∼ N (β, τ 2 ), with a small random effects standard deviation, τ = 0.05, the estimated power of these procedures was very similar to their power under the fixed effects model (Figure 2) . If the random effects standard deviation was τ = 0.5, there was enough heterogeneity in association effects across studies that the log odds were positive in some studies and negative in others, leading to a reduction in the meta-analytic summary estimate of association, and to substantial loss in power compared to all other procedures (Figure 3 ). For example, for S = 5 with n s = 400 (Figure 3) , an expected log-odds ratio of log(1.6) was required to attain 80% power for the meta-analytic approach. On the other hand, the sum of Wald tests or Fishers combination are invariant to sign changes of the effects, and had very high power. For example, even for mean log-odds ratio β = 0, the power of those two procedures was near 80% for S = 10 with n s = 200 and S = 5 with n s = 400. The combined list procedure also had much higher power than the meta-analytic approaches, for example, 82% for a mean log-odds ratio of log(1.4) for S = 5 with n s = 400. Again, for the fixed effects meta-analysis and the random effects meta-analysis with the critical region defined by the χ 2 1,1−α quantile, the lines completely overlap and are indistinguishable in Figures 2 and 3 .
The power of the Liptak-Stouffer combination of p-values for all settings studied for the figures was very close to the power of the Fisher statistic and therefore is not presented. For example, for the fixed effects model presented in Figure 1 , for an OR = 1.5, with 200 cases and 200 controls for 10 studies, the power of the Fisher combination was 0.9581 and for the Liptak-Stouffer combination was 0.9535. For 400 cases and 400 controls and 5 studies, the power for an OR = 1.4 was 0.8057 for Fisher's and 0.8167 for the Liptak-Stouffer combination of p-values.
Fewer studies with larger sample size (S = 5, n s = 400) resulted in higher power than more studies with the same total number of subjects (S = 10 and n s = 200) for all procedures (with the exception of the meta-analytic approaches, for which the power was the same) under the fixed effects model and under the random effects model with τ = 0.05 (Figures 1  and 2 ). When τ = 0.5, however, the power of all approaches but the combined list was larger for S = 10 studies with n s = 200 (Figure 3 ).
DISCUSSION
As is evident from the literature on detection probability (Gail et al., 2008a (Gail et al., , 2008b and power calculations (Skol et al., 2006 (Skol et al., , 2007 , large sample sizes are needed to have a good chance to discover diseaseassociated SNPs with odds ratios commonly found in GWA studies. Because in many settings the available studies are too small, there is a need to combine information from several studies. Our results indicate that the fixed effects meta-analysis has higher DP than other methods. Only when there is severe heterogeneity in association effects across studies such that the log odds is positive in some studies and negative in others can methods such as sum of Wald tests or Fishers combination of p-values have larger DP than the fixed effects and random effects meta-analytic approaches. Loughin (2004) found, in an extensive simulation study of the power of various quantile combinations methods for p-values, that Fisher's method had very good power compared to other transformation functions (including normal and logistic) when a minority of the tests provided most of the evidence against the null hypothesis. When signal was distributed equally over all p-values, the normal transformation proved to be somewhat more powerful than Fisher's approach. We therefore also assessed the performance of the Liptak-Stouffer combination of p-values. In our simulation studies, under both the fixed effects and the random effects model for the disease associated SNPs, Fisher's combination of p-values had higher DP than the Liptak-Stouffer combination of p-values, but had very similar power. Although differences in LD patterns across populations can result in associations in opposite directions, as illustrated by CDKN1AS31R, in the supplement to Zeggini et al. (2008) , in most circumstances the heterogeneity will not be sufficient to render the meta-analytic approaches less powerful than other approaches. The method of combining lists of promising SNPs from each of the component studies has the lowest DP in most circumstances, and especially when there are many small studies of comparable size. Our results for power give a similar ranking of procedures to combine information as for DP, despite the fact that these two criteria are far from equivalent (Gail et al., 2008b ).
We used the critical values from a one degreeof-freedom chi-square distribution in power calculations for the random effects meta-analytic procedure discussed by DerSimonian and Laird (1986) . Under the strong null hypothesis that the log odds is strictly zero, we conducted simulations and verified that such critical values yielded proper size in simulations for α = 0.1 and α = 0.01. It is not certain that the size is nominal for α = 10 −7 , however, and therefore the power from the random effects metaanalytic approach may not be strictly comparable to that of the fixed effects meta-analysis. If in fact null SNPs satisfy only a weak null hypothesis, namely, that their log odds have mean zero but vary about this mean, then a critical value based on an F distribution might be more appropriate (Follmann and Proschan, 1999 ). Using such a critical value reduces power to almost zero, however, as shown in Fig-Fig. 3 . Power of various approaches for combing data from S = 10 GWAS studies with ns = 200 cases and ns = 200 controls each (blue lines) or S = 5 studies with ns = 400 cases and ns = 400 controls each (red lines) under the random effects model for disease-associated SNPs, β s ∼N (β, 0.5 2 ), with η = 0.2673.
ures 1, 2 and 3. In Section 2 we argue that a strong null hypothesis is plausible. We assumed that the same platform was used to analyze the samples in each study and thus that data were available on the same set of SNPs in each study. Zeggini et al. (2008) used two algorithms that employed Hapmap data to impute missing SNPs in some studies. We also assumed that adequate quality control procedures had been followed in all the studies and that there was proper control for population stratification. Otherwise, the assumption of a strong null hypothesis for nondisease-associated SNPs would not hold.
APPENDIX Variance Computation for Model (5)
For ease of exposition we omit the SNP specific subscript, and denote (5) 
where the index j refers to the jth subject in study s. The first set of equations corresponds to the study specific intercept parameters, and the last equation corresponds to the common log-odds ratio parameter β. The variance σ 2 S = var(β) = (I 22 −I 21 I −1 11 I 12 ) −1 , where I 11 , I 12 , I 22 are submatrices of the information matrix I from the prospective likelihood:
(I 11 ) ij = E(∂ 2 /∂µ i ∂µ j log L), (I 21 ) j = E(∂ 2 /∂µ j ∂β log L),
The expectations of the second derivatives and crossderivatives of the prospective log-likelihood are taken with respect to retrospective sampling distributions f s x = P s (X = x|Y = 1) and g s x = P s (X = x|Y = 0), for cases and controls respectively.
As the studies are independent, I 11 is a diagonal matrix with the expected second derivatives of the study specific intercept parameters on the diagonal. Thus, the information matrix reduces to 
